Overview
- Pfizer reported first‑quarter revenue growth of about 5% year over year as net income fell 9% and adjusted profit dropped roughly 18%, signaling margin pressure.
- The dividend now yields about 6.7%, with earnings per share of $0.47 just topping the $0.43 quarterly payout and free cash flow of $2.2 billion below the roughly $2.4 billion paid to shareholders.
- Management kept 2026 sales guidance at $59.5 billion to $62.5 billion and expects about $5 billion from COVID products, while warning patent losses could trim this year’s revenue by roughly $1.5 billion.
- Pfizer is leaning on oncology for future growth after buying Seagen, with launched and acquired products up 22% operationally in Q1 and Padcev cancer‑drug sales up 39% to $591 million.
- The stock trades at under nine times forward earnings, drawing income seekers even as analysts caution the payout could face pressure if cash flow fails to improve.